San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Eclipse Bioinnovations is raising $14,950,020.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Peter Chu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Eclipse Bioinnovations
Eclipse Bioinnovations Inc. is a San Diego biotechnology start-up company focused on specialized genomics technologies. Our major focus is the development of next-generation sequencing products and services to profile binding sites for RNA binding proteins, using enhanced crosslinking and immunoprecipitation (eCLIP-seq).

To learn more about Eclipse Bioinnovations, visit http://eclipsebio.com/

Contact:
Peter Chu, Chief Executive Officer
855-727-2547
https://www.linkedin.com/in/pchu77/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved